CLF Surges 31% After EPS Revision, NVCR and GENI Follow on Strong Outlooks
Cleveland-Cliffs (CLF) jumped 31.1% after analysts raised its forward EPS growth estimate by 36.7 percentage points, supported by a strong Q2 earnings beat and bullish Q3 guidance. NovoCure (NVCR) gained 11.6% following a record revenue quarter and upward guidance revision. Other top movers include Genius Sports (GENI) +13.3% and Chegg (CHGG) +15.8%, each benefiting from upward EPS estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CLF | Basic Materials | 2026-07-20 | +36.7pp | +31.1% |
| CHGG | Consumer Defensive | 2026-07-19 | N/A | +15.8% |
| GENI | Communication Services | 2026-07-22 | +1.4pp | +13.3% |
| NVCR | Healthcare | 2026-07-22 | N/A | +11.6% |
| BZUN | Consumer Cyclical | 2026-07-19 | N/A | +11.2% |
Why did CLF stock jump in July 2026?
CLF jumped 31.1% (from $8.98 to $11.77) after analysts raised its forward EPS growth estimate from 198.6% to 235.3% on July 20.
The steelmaker then reported Q2 adjusted EBITDA tripling to $286M and guided Q3 EBITDA to more than double to $575M. Strong automotive demand and Section 232 tariffs are boosting pricing power. The EPS revision was detected by our screener just before the earnings report, capturing the early signal.
CLF EPS revision history → · Screener snapshot from 2026-07-20 →
FAQ: CLF
Why did CLF stock jump?
CLF jumped 31.1% after analysts raised its forward EPS growth estimate from 198.6% to 235.3% on July 20, followed by a strong Q2 earnings beat with EBITDA tripling.
Is CLF a buy after the rally?
The EPS revision and Q3 guidance of $575M EBITDA suggest continued momentum, but the stock has run 31% in a week, so consider valuation relative to steel price outlook.
What caused CLF's surge?
The surge was triggered by an upward EPS revision detected on July 20, then reinforced by a Q2 earnings report showing adjusted EBITDA tripling and a bullish Q3 outlook.
Why did CHGG stock jump in July 2026?
CHGG jumped 15.8% (from $0.82 to $0.95) after analysts revised its forward EPS growth estimate to 50.0% on July 19.
The revision signals expected earnings improvement as Chegg restructures its subscription model and cuts costs. No major news broke during the period, so the move was driven entirely by the estimate upgrade. The high growth rate reflects a low base as the company pivots from losses to profitability.
CHGG EPS revision history → · Screener snapshot from 2026-07-19 →
FAQ: CHGG
Why did CHGG stock jump?
CHGG jumped 15.8% after analysts revised its forward EPS growth estimate to 50.0% on July 19, signaling expected profitability improvement.
Is CHGG a buy after the rally?
The 50% EPS growth rate is high but from a low base; monitor subscription trends and cost restructuring execution.
What is CHGG's EPS growth estimate?
Analysts now estimate CHGG's forward EPS growth at 50.0%, up from a prior lower estimate, reflecting turnaround expectations.
Why did GENI stock jump in July 2026?
GENI jumped 13.3% (from $6.37 to $7.22) after analysts raised its forward EPS growth estimate from 1069.9% to 1071.2% on July 22.
The extreme percentage growth reflects a near-zero earnings base; the company is expected to turn profitable. Sentiment is supported by growing demand for sports data and technology services. The tiny revision margin (1.4pp) still signals increased confidence in the trajectory.
GENI EPS revision history → · Screener snapshot from 2026-07-22 →
FAQ: GENI
Why did GENI stock jump?
GENI jumped 13.3% after analysts raised its forward EPS growth estimate from 1069.9% to 1071.2% on July 22, supported by growing sports technology revenue.
Is GENI a buy after the rally?
The extreme percentage growth reflects a low earnings base; the company is approaching profitability, but the narrow revision margin suggests modest confidence.
What caused GENI's surge?
The surge followed a minor upward EPS revision; investor optimism around sports data monetization and partnerships likely contributed.
Why did NVCR stock jump in July 2026?
NVCR jumped 11.6% (from $15.57 to $17.37) after analysts revised its forward EPS growth estimate to 33.6% on July 22.
The following day, NovoCure reported record Q2 revenue of $184M (+16% YoY) and raised full-year guidance. Optune product adoption grew 18% with European approval for pancreatic cancer. The earnings beat reinforced the upward estimate revision.
NVCR EPS revision history → · Screener snapshot from 2026-07-22 →
FAQ: NVCR
Why did NVCR stock jump?
NVCR jumped 11.6% after analysts revised its forward EPS growth estimate to 33.6% on July 22, soon followed by record Q2 revenue of $184M.
Is NVCR a buy after the rally?
Record revenue, growing patient adoption, and raised guidance support the re-rating, but consider the ongoing net loss and competition.
What caused NVCR's surge?
The catalyst was an upward EPS estimate revision ahead of a strong Q2 earnings report showing 16% revenue growth and improved margins.
Why did BZUN stock jump in July 2026?
BZUN jumped 11.2% (from $2.51 to $2.79) after analysts revised its forward EPS growth estimate to 58.1% on July 19.
The revision reflects expectations of a recovery in Chinese e-commerce and brand management services. No earnings news was released during the window, so the price gain is attributable to the estimate upgrade alone. The high growth rate suggests margin improvements from cost controls.
BZUN EPS revision history → · Screener snapshot from 2026-07-19 →
FAQ: BZUN
Why did BZUN stock jump?
BZUN jumped 11.2% after analysts revised its forward EPS growth estimate to 58.1% on July 19, reflecting expected earnings recovery.
Is BZUN a buy after the rally?
The high growth rate signals a potential turnaround in Chinese e-commerce services, but geopolitical risks remain.
What is BZUN's EPS growth estimate?
Analysts estimate BZUN's forward EPS growth at 58.1%, driven by cost optimization and a recovering Chinese consumer market.
Today's top performers highlight that upward EPS revisions are being rewarded across sectors, with basic materials and healthcare leading on tangible earnings beats and guidance raises. The market is pricing in a recovery in steel demand and biotech product expansion.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →